Financial Analysis: Intellia Therapeutics Inc (NTLA)’s Ratios Unveil Key Insights

Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

As of close of business last night, Intellia Therapeutics Inc’s stock clocked out at $22.94, down -2.71% from its previous closing price of $23.58. In other words, the price has decreased by -$2.71 from its previous closing price. On the day, 0.66 million shares were traded. NTLA stock price reached its highest trading level at $23.62 during the session, while it also had its lowest trading level at $22.685.

Ratios:

To gain a deeper understanding of NTLA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.21 and its Current Ratio is at 7.21. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.09.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 23, 2024, Downgraded its rating to Neutral and sets its target price to $32 from $136 previously.

On April 13, 2023, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $66.Canaccord Genuity initiated its Buy rating on April 13, 2023, with a $66 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 01 ’24 when Clark Eliana sold 405 shares for $22.93 per share. The transaction valued at 9,287 led to the insider holds 71,470 shares of the business.

Verwiel Frank sold 1,505 shares of NTLA for $37,625 on Jun 17 ’24. The Director now owns 17,948 shares after completing the transaction at $25.00 per share. On Mar 04 ’24, another insider, BASTA JAMES, who serves as the EVP, General Counsel of the company, sold 2,297 shares for $32.99 each. As a result, the insider received 75,778 and left with 81,571 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 2330222336 and an Enterprise Value of 1745453568. For the stock, the TTM Price-to-Sale (P/S) ratio is 50.69 while its Price-to-Book (P/B) ratio in mrq is 2.32. Its current Enterprise Value per Revenue stands at 37.972 whereas that against EBITDA is -3.395.

Stock Price History:

Over the past 52 weeks, NTLA has reached a high of $38.79, while it has fallen to a 52-week low of $19.37. The 50-Day Moving Average of the stock is -4.60%, while the 200-Day Moving Average is calculated to be -12.04%.

Shares Statistics:

It appears that NTLA traded 1.65M shares on average per day over the past three months and 1044530 shares per day over the past ten days. A total of 101.58M shares are outstanding, with a floating share count of 99.69M. Insiders hold about 1.86% of the company’s shares, while institutions hold 86.01% stake in the company. Shares short for NTLA as of 1722384000 were 13370113 with a Short Ratio of 8.39, compared to 1719532800 on 13251610. Therefore, it implies a Short% of Shares Outstanding of 13370113 and a Short% of Float of 15.57.

Most Popular